Placebo response in trials with patients with anxiety, obsessive-compulsive and stress disorders across the lifespan: a three-level meta-analysis

Conclusions Placebo response is substantial in SSRI and SNRI trials for anxiety, obsessive-compulsive and stress-related disorders. Clinicians and researchers should accurately interpret the benefits of pharmacological agents in contrast to placebo response. PROSPERO registration number CRD42017069090.

http://mentalhealth.bmj.com/cgi/content/short/26/1/e300630?rss=1

Source: Evidence-Based Mental Health - May 4, 2023 Category: Psychiatry & Psychology Authors: Motta, L. S., Gosmann, N. P., Costa, M. d. A., Jaeger, M. d. B., Frozi, J., Grevet, L. T., Spanemberg, L., Manfro, G. G., Cuijpers, P., Pine, D. S., Salum, G. Tags: Open access Pharmacological treatments Source Type: research